SOTERA HEALTH COMPANY Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-06: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-06 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-05 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-05 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-05 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-05 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-08 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-08 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | Under the Company’s policies and practices, in general, the Company does not grant equity awards when in possession of material non-public information. While the Company does not have predetermined, fixed dates upon which grants must be made, in general, our broad-based equity awards (including gran… | |
| 2026-04-08 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Under the Company’s policies and practices, in general, the Company does not grant equity awards when in possession of material non-public information. While the Company does not have predetermined, fixed dates upon which grants must be made, in general, our broad-based equity awards (including gran… | |
| 2026-04-08 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-08 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | As a general matter, the LDC Committee does not take material nonpublic information into account when determining the timing and terms of such awards. Due to the grant timing described above, grants are generally made during open trading windows. The grant process and timing described above is used … | |
| 2026-04-08 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-04-08 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-08 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | (a) (b) (1) (c) (1)(2) (d) (3) (e) (3)(4) (f) (5) (g) (5)(6) (h) (7) (i) (8) Value of initial fixed $100 investment based on: Year Summary Compensation Table Total for CEO Compensation Actuall… | |
| 2026-04-08 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | (1) The CEO in all five reporting years is Michael B. Petras, Jr.; reflects compensation amounts reported in the Summary Compensation Table (“SCT”) for Mr. Petras for the years ended December 31, 2025, 2024, 2023, 2022 and 2021, respectively. (3) The following non-CEO PVP NEOs are included in the av… | |
| 2026-04-08 DEF 14A | Peer Group Issuers Footnote | 2025-01-01..2025-12-31 | (6) For purposes of this PVP disclosure, our peer group is the S&P 500 Healthcare Index (the “Peer Group”). | |
| 2026-04-08 DEF 14A | Non Gaap Measure Description | Measure: 2 | 2025-01-01..2025-12-31 | (8) For purposes of this PVP disclosure, the Company-Selected Measure is Adjusted EBITDA, which is described below. |
| 2026-04-08 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | The tables below disclose the amounts deducted from, and added to, the Summary Compensation Table total compensation amounts to calculate the Compensation Actually Paid for each of the applicable years, for the CEO and average non-CEO NEOs, as shown in columns (c) and (e) of the PVP Table, respectiv… | |
| 2026-04-08 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | The tables below disclose the amounts deducted from, and added to, the Summary Compensation Table total compensation amounts to calculate the Compensation Actually Paid for each of the applicable years, for the CEO and average non-CEO NEOs, as shown in columns (c) and (e) of the PVP Table, respectiv… | |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$8.02M |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $12.81M |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $2.28M |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$1.01M |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.66M |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $2.57M |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $329.60K |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$145.62K |
| 2026-04-08 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | ||
| 2026-04-08 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2025-01-01..2025-12-31 | ||
| 2026-04-08 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | ||
| 2026-04-08 DEF 14A | Total Shareholder Return Vs Peer Group | 2025-01-01..2025-12-31 | ||
| 2026-04-08 DEF 14A | Tabular List Table | 2025-01-01..2025-12-31 | The following financial performance measures represent, in the Company’s assessment, the most important financial measures the Company used to link our CEO and Non-CEO NEO CAP for 2025 to Company performance: Financial Performance Measures Free Cash Flow Adjusted EBITDA Revenue Ste… | |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueOfStockAndOptionAwardsForfeitedDuringTheCoveredYear; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | |
| 2026-04-08 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueOfStockAndOptionAwardsForfeitedDuringTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | |
| 2026-02-24 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-24 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-24 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-24 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-24 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |